Ipsen SA of France is out-licensing two of its peptide therapeutics programmes that target metabolic and gastrointestinal disorders and obesity to Rhythm Pharmaceuticals, a venture capital-backed company in Boston, Massachusetts. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
